Ventilator News and Research

RSS

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Allergan plc today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San Diego.

8 Oct 2015

New study calls for new treatments for carbapenem-resistant Enterobacteriaceae infection

Researchers at The Medicines Company presented data from a multi-national cohort that demonstrates the mortality and morbidity, and poor outcomes, associated with current therapies in patients with infections due to carbapenem-resistant Enterobacteriaceae (CRE). The data from this analysis has guided the design of the company’s on-going clinical studies of its Phase 3 compound, CARBAVANCE® (meropenem/RPX7009) and was presented at the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy and Infection (ICC) joint meeting in San Diego, CA.

22 Sep 2015

Higher doses of hydrocortisone not linked to neurodevelopmental impairments in low birth weight infants

Hydrocortisone is one of the 15 most frequently prescribed medications in extremely low birth weight (?1000 g) infants in the newborn intensive care unit (NICU).

21 Sep 2015

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to AR-301, the Company's fully human anti-Staphylococcal alpha-toxin IgG1 monoclonal antibody (mAb).

11 Sep 2015

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics Inc., a subsidiary of Vernalis plc, today announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to adult patients and physicians in the United States.

8 Sep 2015

Organ donor honored at Reagan UCLA Medical Center

Two years ago, Rachel Greenberg went out to run a few errands. While she was gone, her husband Glenn suffered a massive brain hemorrhage. He was immediately taken to Ronald Reagan UCLA Medical Center where physicians explained he had suffered the worst kind of brain bleed.

25 Jul 2015

Innovation in anaesthesia: an interview with Matti Lehtonen, GE Healthcare

The spectrum of patients seen today, from pre-term infants to the morbidly obese to the longer living elderly, is wider than ever before and increasingly more challenging with patients often presenting with multiple co-morbidities. This puts a huge strain on healthcare providers who are facing increasing challenges such as cost pressure and staff shortages.

14 Jul 2015

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.

8 Jul 2015

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to its fully human monoclonal antibody Aerucin for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

30 Jun 2015

Basilea announces UK launch of broad-spectrum Cephalosporin Zevtera for first-line treatment of pneumonia

Basilea Pharmaceutica AG today announces the UK launch of its broad-spectrum Cephalosporin Zevtera (Ceftobiprole medocaril) for the first-line treatment of serious bacterial pneumonia.

25 Jun 2015

Warm Springs Specialty Hospital of New Braunfels achieves Gold Seal of Approval for Respiratory Failure Certification

Warm Springs Specialty Hospital of New Braunfels, a Post Acute Medical facility, today announced that it has earned The Joint Commission's Gold Seal of Approval for Respiratory Failure Certification. The Gold Seal of Approval is a symbol of quality that reflects an organization's commitment to providing safe and effective patient care.

17 Jun 2015

Critical care Breathe Technologies Life2000 Ventilation System receives FDA clearance

Breathe Technologies, Inc., a developer and manufacturer of medical technologies for patients with respiratory insufficiency and neuromuscular diseases, announced today that the U.S. Food and Drug Administration has granted 510(k) clearance for its critical care Breathe Technologies Life2000 Ventilation System, which is intended to provide continuous or intermittent ventilatory support for the care of individuals who require mechanical ventilation.

15 Jun 2015

Breathe NIOV System improves exercise duration among patients with chronic respiratory disease

Breathe Technologies, a developer and manufacturer of innovative medical technologies for patients with respiratory insufficiency diseases and neuromuscular diseases, announced new data today demonstrating that use of its Non-Invasive Open Ventilation (NIOV) System in pulmonary rehabilitation was associated with significant improvement in mean exercise duration change (approximately 63 percent) among patients with chronic respiratory disease.

8 Jun 2015

Transitional and progressive care can help patients achieve functional recovery faster in post-acute care

Transitional care has emerged as a way to reduce hospital readmissions, and progressive care nurses can play an integral role in efforts to help patients achieve functional recovery faster in post-acute care, according to an article in the June issue of Critical Care Nurse.

3 Jun 2015

Weight loss can improve outcomes in lung transplant patients

Obesity is a complicating factor for many surgical patients. In a recent study published in the Journal of Heart and Lung Transplantation, Mayo Clinic researchers have shown that losing weight can have a positive impact on outcomes for lung transplant patients.

18 May 2015

CHOP's patient safety team recognized for work alarm fatigue in hospital units

A patient safety team at The Children's Hospital of Philadelphia who analyzed the problem of alarm fatigue in hospital units has been recognized for the best research paper of 2014 in a journal dedicated to biomedical technology.

8 May 2015

Study finds hospital variation in outcomes for extremely premature infants

Extremely premature infants born at 22 to 25 weeks of gestation have low rates of survival, and many of those infants who live have severe or moderate neurodevelopmental impairments. Thus, clinicians and families face the extremely difficult decision to either provide active, potentially lifesaving treatment at birth, or just provide comfort care.

7 May 2015

Fecal transplantation cures C. diff infection, eliminates multi-drug resistant pathogens

A fecal microbiota transplant (FMT) not only cured a case of Clostridium difficile (C. diff) infection in a 66 year old man; it eliminated populations of multi-drug resistant organisms both in the patient's gastrointestinal tract, and several other body sites.

7 May 2015

Adult survivors of preterm births at higher risk of developing COPD

Adult survivors of preterm births may have a lung capacity that resembles the healthy elderly or casual smokers by the time they reach their early 20s, according to a University of Oregon study.

30 Apr 2015

Nabriva Therapeutics completes $120 million Series B financing

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative bacteria, today announced the successful completion of a $120 million Series B financing.

7 Apr 2015